Bicalutamide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Bicalutamide: From Prostate Cancer to Hypertrichosis
One-Sentence Summary
Bicalutamide is a non-steroidal antiandrogen originally used for the treatment of prostate cancer, functioning by competitively blocking the androgen receptor (AR) to suppress androgen-driven cell growth. The TxGNN model predicts it may be effective for hypertrichosis, with 0 clinical trials and 1 publication currently supporting this direction — specifically an expert commentary describing how Bicalutamide reduced Minoxidil-induced excess hair growth in female pattern hair loss patients.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Prostate cancer (androgen deprivation / antiandrogen therapy) |
| Predicted New Indication | Hypertrichosis |
| TxGNN Prediction Score | 99.69% |
| Evidence Level | L4 |
| Philippines Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, formal mechanism of action (MOA) data from the regulatory database is not available for this report. Based on well-established pharmacological knowledge, Bicalutamide is a selective, competitive androgen receptor (AR) antagonist. It binds to AR and prevents testosterone and dihydrotestosterone (DHT) from activating downstream gene transcription — the central mechanism behind its clinical use in prostate cancer, where androgen signaling drives tumor cell proliferation.
The connection to hypertrichosis lies in the shared biology of androgen signaling in hair follicles. Androgens acting through AR are known to promote terminal hair growth in androgen-sensitive body areas such as the face, chest, arms, and legs. In androgen-dependent hypertrichosis — particularly drug-induced forms such as Minoxidil-associated hypertrichosis — blocking AR activity could theoretically reduce unwanted hair growth. The single supporting publication (PMID 35304167) is an expert letter commenting on Bicalutamide’s clinical use to reverse Minoxidil-induced hypertrichosis in female pattern hair loss patients, providing a real-world proof-of-concept signal.
However, hypertrichosis is a heterogeneous condition with many subtypes. Congenital forms (e.g., Ambras syndrome caused by 8q chromosomal abnormalities) and genetic hair shaft structural disorders are driven by mechanisms entirely unrelated to androgen signaling, and would not be expected to respond to AR blockade. This TxGNN prediction is most mechanistically plausible for androgen-dependent acquired hypertrichosis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35304167 | 2022 | Letter / Comment | Journal of the American Academy of Dermatology | Expert commentary on Bicalutamide’s ability to improve Minoxidil-induced hypertrichosis in female pattern hair loss patients; supports the concept of AR blockade as a clinically observable hair growth suppressor |
Philippines Market Information
No registrations found in the Philippines FDA database. Bicalutamide is not currently marketed in the Philippines.
Cytotoxicity
Bicalutamide is classified as an antineoplastic agent due to its primary indication in prostate cancer. However, it is a hormone therapy (antiandrogen), not conventional cytotoxic chemotherapy.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Hormone therapy / Antiandrogen — non-cytotoxic, targeted mechanism of action |
| Myelosuppression Risk | Low (antiandrogen hormone therapies do not cause significant bone marrow suppression) |
| Emetogenicity Classification | Low |
| Monitoring Items | Liver function tests (LFTs) — hepatotoxicity has been reported with Bicalutamide; PSA monitoring for oncological use; periodic CBC recommended |
| Handling Protection | Standard pharmaceutical handling; dedicated cytotoxic drug handling precautions are generally not required for antiandrogen hormone therapies |
Safety Considerations
Detailed official warning labels and contraindications from the Philippines FDA package insert were not available in the current evidence pack. Please refer to the package insert for complete safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The current evidence for Bicalutamide in hypertrichosis rests on a single expert letter with no primary clinical data and zero registered clinical trials; while the mechanistic rationale (AR blockade suppressing androgen-dependent hair growth) is biologically coherent, the evidence base is insufficient to support clinical development or formulary consideration at this stage.
To proceed, the following is needed:
- Prospective pilot study or structured case series directly assessing Bicalutamide’s efficacy in patients with confirmed androgen-dependent hypertrichosis
- Patient subgroup definition: only androgen-dependent acquired hypertrichosis (e.g., drug-induced, hyperandrogenism-associated) is mechanistically expected to respond; congenital and genetic subtypes must be excluded from scope
- Complete MOA and safety data retrieval from DrugBank (DrugBank ID: DB01128)
- Philippines FDA package insert or equivalent labeling document to confirm contraindications, hepatic monitoring requirements, and local regulatory standing
- Assessment of appropriate dose and formulation for a dermatological indication, which may differ substantially from oncological dosing regimens
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.